ArticleNature communications2024
Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights.
Abstract read
In one paragraph
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Insights into pet-based radiogenomics in oncology: an updated systematic review.European journal of nuclear medicine and molecular imaging · 2025Pooled it
- Genomic instability, postoperative recurrence and therapeutic vulnerabilities in resectable non‑small cell lung cancer (Review).Oncology reports · 2026Review
- Smoking reshapes systemic metabolic coordination across lung cancer subtypes: a multicenter total-bodyEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Application advances of habitat imaging based on CT or PET/CT: a systematic review.La Radiologia medica · 2026Review
- Enhanced recurrence risk stratification for stages Ⅱ-Ⅲ breast cancer using MRI-based structure habitat imaging.European radiology · 2026Article
- Multimodal MRI habitat atlas for personalised re-haemorrhage risk prediction in brainstem cavernous malformations.Stroke and vascular neurology · 2026Article
- PET/CT imaging for assessment of tumor immunotherapy response: a new perspective on tumor metabolic reprogramming and immune escape.La Radiologia medica · 2026Review
- Specific PET Imaging for Precision Management of Lung Cancer: Advances, Clinical Translation and Future Directions.Chemical & biomedical imaging · 2026Review
- A High-Sensitivity Circulating Nucleic Acid Sequencing Assay for Assessing Treatment Response to Alectinib in a Pediatric Patient With ALK-Rearranged Non-Small Cell Lung Cancer.Pediatric blood & cancer · 2026Article
- MRI-based quantification of intratumoral heterogeneity for predicting recurrence risk in ER+/HER2- breast cancer.Insights into imaging · 2026Article
- Habitat model based on CEUS for noninvasive prediction of EGFR mutation status in peripheral NSCLC.BMC cancer · 2026Article
- Heterogeneity Analyzed by CT-Based Habitat Analysis for Clinical Management of Cancers: A Narrative Review.The Kaohsiung journal of medical sciences · 2026Review
- Article
- Multimodal multitask deep learning for grading management system in non-small cell lung cancer.Nature communications · 2026Article
- Development and validation of a radiomics-dosiomics model for predicting radiotherapy response in locally advanced, unresectable non-small cell lung cancer: a multi-center study.Scientific reports · 2026Article
- Development of a Prediction Model for Progression Risk in High-Grade Gliomas Based on Habitat Radiomics and Pathomics.Annals of clinical and translational neurology · 2026Article
- Nanomaterials reshaping cancer radiotherapy: Radiosensitization mechanisms, delivery and theranostic platforms, multimodal synergy, and clinical translation strategies.Materials today. Bio · 2026Review
- Molecular residual disease-based novel modality of postoperative management for non-small-cell lung cancer (REMODEL): Protocol for a prospective multicenter study.Journal of translational internal medicine · 2026Article
- Predictive value of primary tumorCancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Predictions of Oncotype DXBioengineering (Basel, Switzerland) · 2026Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors.
Sheeba J Sujit *Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-8302-7046
Muhammad Aminu *Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-9903-8812
Tatiana V KarpinetsDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pingjun ChenDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-0528-1713
Maliazurina B SaadDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Morteza SalehjahromiDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
John D BoomDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0009-0004-6625-318X
Mohamed QayatiDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
James M GeorgeDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-9723-6444
Haley AllenNatural Sciences, Rice University, Houston, TX, USA.
Mara B AntonoffDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-6247-9537
Lingzhi HongDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-6553-3279
Xin HuDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Simon HeekeDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-5916-534X
Hai T TranDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xiuning LeDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-8554-1185
Yasir Y ElaminDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-5312-909X
Mehmet AltanDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-9229-156X
Natalie I VokesDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-3766-5335
Ajay SheshadriDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-8091-0180
Julie LinDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jianhua ZhangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-5412-9860
Yang LuDepartment of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-9571-4679
Carmen BehrensDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Myrna C B GodoyDepartment of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Carol C WuDepartment of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-1005-0995
Joe Y ChangDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Caroline ChungDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
David A JaffrayDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ignacio I WistubaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
J Jack LeeDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-5469-9214
Ara A VaporciyanDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Don L GibbonsDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-2362-3094
John HeymachDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-9068-8942
Jianjun ZhangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-7872-3477
Tina CasconeDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-3008-5407
Jia WuDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jwu11@mdanderson.org.ORCID http://orcid.org/0000-0001-8392-8338
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MUNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V., MINNA, JOHN D. · 1996 to 2024
$57.4MRadioimmunogenomic Habitat Phenotypes to Predict Efficacy of Neoadjuvant Immunotherapies in Non-Small Cell Lung CancerR01CA262425 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CASCONE, TINA, WU, JIA · 2021 to 2025
$3.2MIntegrated blood and radiomic subtyping to guide immunotherapy treatment selection and early response assessment in metastatic non-small cell lung cancerR01CA276178 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Natalie Vokes, Jia Wu · 2023 to 2026
$2.6MQUANTITATIVE IMAGING BIOMARKERS OF TREATMENT RESPONSE AND PROGNOSIS IN BREAST CANCERR00CA218667 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WU, JIA · 2020 to 2022
$747kNCI NIH HHS P30 CA016672NCI NIH HHS P50 CA070907NCI NIH HHS R00 CA218667NCI NIH HHS R01 CA262425NCI NIH HHS R01 CA276178
Abstract
While we recognize the prognostic importance of clinicopathological measures and circulating tumor DNA (ctDNA), the independent contribution of quantitative image markers to prognosis in non-small cell lung cancer (NSCLC) remains underexplored. In our multi-institutional study of 394 NSCLC patients, we utilize pre-treatment computed tomography (CT) and
Indexed as
Carcinoma, Non-Small-Cell LungLung NeoplasmsFluorodeoxyglucose F18HumansNeoplasm Recurrence, LocalPositron-Emission TomographyPositron Emission Tomography Computed TomographyRadiopharmaceuticalsRetrospective StudiesTomography, X-Ray ComputedFluorodeoxyglucose F18Radiopharmaceuticals
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.